Active Ingredient(s):Sutimlimab-jome FDA Approved: * February 4, 2022 Pharm Company: *BIOVERATIV THERAPEUTICS INC
Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD). It is given by intravenous infusion. Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro.
This drug is being developed by Bioverativ, a Sanofi company. Sutimlimab was approved for medical use in the United Stat...
* May have multiple approval dates, manufacturers, or labelers.